393P EFFICACY OF ERIBULIN IN A SECOND-LINE OR LATER SETTING IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC): A POOLED ANALYSIS

C Twelves,Javier Cortes,Martin Olivo,Yi He,Ahmad Awada, Bexley Wing

Annals of Oncology（2014）

引用 1|浏览13

暂无评分

摘要

Aim: Eribulin (E) is under review by the European Medicines Agency for use as a second-line and later therapy for pts with locally advanced/MBC who have advanced after prior chemotherapy. To assess the efficacy of E in this setting, we conducted pooled analyses of data from 2 phase 3 open-label studies in pts with locally advanced/MBC.

查看译文

关键词

metastatic breast cancer,eribulin,breast cancer,efficacy,second-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要